MRVL and MBCOF Related Headlines
Go Back- Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
- Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
- Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204
- Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
- Marvel Biosciences closes private placement raising $1.6 million
- Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
- Marvel Biosciences updates non-brokered private placement of up to $3M
- Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
- Marvel Biosciences extends private placement deadline to Sept. 14
- Marvel Biosciences Announces Extension to Closing Date of Private Placement
- Marvel Biosciences reports MB-204 preclinical results in Fragile X model
- Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
- New Autism Research to be Presented at European Purine Scientific Meeting
- Marvel Biosciences receives Australian patent allowance for MB-204
- Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
- Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
- Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
- Marvel Biosciences secures funding for autism drug trial from 5 Horizons
- Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
- Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
- Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
MRVL and MBCOF Related Press Releases
Go Back- Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
- Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
- Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
- Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
- Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million
- Marvel Biosciences Announces Extension to Closing Date of Private Placement
- Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
- New Autism Research to be Presented at European Purine Scientific Meeting
- Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
- Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
- Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
- Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
- Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
- Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
